Evotec SE (EVO) Amortization (2021 - 2022)

Evotec SE's (EVO) quarterly Amortization came in at $495.84 in Q2 2022, down 99.92% quarter-over-quarter from $615015.9 in Q4 2021.

Evotec SE (EVO) Amortization (2021 - 2022) Analysis & Trends

Evotec SE has disclosed Amortization across 2 years of filings, most recently posting $495.84 for Q2 2022.

Amortization for Q2 2022 came in at $495.84, changed N/A year-over-year; the trailing twelve-month figure through Jun 2022 was $495.84 (changed N/A YoY), and the FY2021 annual result was $615015.9, changed N/A from the prior year.
Amortization came in at $495.84 for Q2 2022 at Evotec SE, down from $615015.9 in the prior quarter.
In the past five years, Amortization ranged from a high of $615015.9 in Q4 2021 to a low of $495.84 in Q2 2022.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Amort. (Qtr)
1	Teva Pharmaceutical Industries	38.34 Bn	34.60 Bn	1.97 Bn	-
2	Zoetis	33.27 Bn	31.33 Bn	1.62 Bn	-
3	United Therapeutics	23.75 Bn	21.60 Bn	648.10 Mn	-
4	Aurora Cannabis	17.11 Bn	17.03 Bn	33.43 Mn	31.86 Mn
5	Neurocrine Biosciences	16.37 Bn	15.05 Bn	800.70 Mn	-
6	Elanco Animal Health	11.78 Bn	11.35 Bn	785.00 Mn	-
7	Alkermes	7.05 Bn	6.54 Bn	-116.06 Mn	-
8	Lantheus Holdings	6.49 Bn	5.99 Bn	230.92 Mn	-
9	Hims & Hers Health	6.19 Bn	5.44 Bn	396.79 Mn	-
10	Evotec SE	583.10 Mn	582.58 Mn	-	-

Download Data